Editorial
Copyright ©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Diabetes. May 15, 2024; 15(5): 818-822
Published online May 15, 2024. doi: 10.4239/wjd.v15.i5.818
Cardioprotective effects of glucagon-like peptide 1 receptor agonists in heart failure: Myth or truth?
Lorenzo Nesti, Domenico Trico
Lorenzo Nesti, Domenico Trico, Department of Clinical and Experimental Medicine, University of Pisa, Pisa 56126, Italy
Lorenzo Nesti, Domenico Trico, Laboratory of Metabolism, Nutrition, and Atherosclerosis, University of Pisa, Pisa 56126, Italy
Author contributions: Nesti L drafted the manuscript; Trico D critically revised the manuscript; All authors have read and approved the final version of the manuscript.
Conflict-of-interest statement: Lorenzo Nesti declares no competing interests. Domenico Trico has served as an advisor for Amarin and has received fees for speaking from AstraZeneca, Eli Lilly and Novo Nordisk.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: Https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Domenico Trico, MD, PhD, Assistant Professor, Department of Clinical and Experimental Medicine, University of Pisa, Via Roma 67, Pisa 56126, Italy. domenico.trico@unipi.it
Received: December 5, 2023
Peer-review started: December 5, 2023
First decision: February 2, 2024
Revised: February 15, 2024
Accepted: March 18, 2024
Article in press: March 18, 2024
Published online: May 15, 2024
Processing time: 156 Days and 20.2 Hours
Core Tip

Core Tip: A growing body of evidence supports the potential cardioprotective properties of glucagon-like peptide 1 receptor agonists (GLP1-RAs) beyond glycemic control, especially in the context of cardiovascular disease. Although the effects of these drugs are consistent in reducing atherosclerosis-related diseases, there is an ongoing debate about the validity of the claim that GLP1-RAs have cardioprotective benefits in heart failure (HF)–a topic that sparks both enthusiasm and skepticism in the scientific and medical communities. Herein we provide a narrative review of the available evidence on the cardioprotective actions of GLP1-RAs in patients with HF, summarizing clinical findings and proposed mechanisms.